Turbocharging Phenotypic Screening with AI to Target mRNA Biology
While the pharmaceutical world is investigating biologics or mRNA-based therapies, Yochi Slonim, Israeli technology and biotech entrepreneur and public speaker on the subject of startup building and positioning, is sticking to the classics -- small molecules -- but his strategy comes with a twist.
Yochi is not a classically trained pharmaceutical scientist. His background is in software, where he has created and sold start-ups that were acquired by large corporations like HP, UGS, and BMC. Yochi took his expertise in software/artificial intelligence (AI) and co-founded Anima Biotech in 2014 to help create a novel way to identify mRNA-targeting drugs and their mechanisms of action.
Topics: AI & Digital